AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22289854 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive phototherapy
Number of subjects: 174
Study 22289854 — intervention group
Group type: COMPARATOR
Intervention: Conservative phototherapy
Number of subjects: 174
Study 20645078 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (mean: 14.7 mg; range: 10‐30 mg)
Number of subjects: 18
Study 20645078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17931510 — intervention group
Group type: EXPERIMENTAL
Intervention: Criterion-based training using surgical simulators
Number of subjects: 17
Study 15819974 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC/EFV/ddI plus HU (500 mg twice daily)
Number of subjects: 54
Study 15819974 — intervention group
Group type: COMPARATOR
Intervention: ABC/EFV/ddI without HU
Number of subjects: 54
Study 11990302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Number of subjects: 27
Study 11990302 — intervention group
Group type: COMPARATOR
Intervention: Native E. coli L-asparaginase
Number of subjects: 27
Study 9139177 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm crank exercise
Number of subjects: 8
Study 9139177 — intervention group
Group type: COMPARATOR
Intervention: Cycle exercise
Number of subjects: 8
Study 8444395 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ciprofloxacin 250 mg p.o.
Number of subjects: 226
Study 8444395 — intervention group
Group type: COMPARATOR
Intervention: Two-day treatment with ciprofloxacin 250 mg bid
Number of subjects: 226
Study 8444395 — intervention group
Group type: COMPARATOR
Intervention: Three-day treatment with ciprofloxacin 2 x 250 mg/day
Number of subjects: 226
Study 2431013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin at 0.25 U/ml
Number of subjects: 26
Study 2431013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin at 0.5 U/ml
Number of subjects: 26
Study 2431013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin at 1 U/ml
Number of subjects: 26
Study 2431013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin (all concentrations)
Number of subjects: 26
Study 30252913 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin DR 1200 mg
Number of subjects: 571
Study 30252913 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin DR 1500 mg
Number of subjects: 571
Study 30252913 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin IR 1000 mg
Number of subjects: 571
Study 30252913 — intervention group
Group type: COMPARATOR
Intervention: Placebo (QD)
Number of subjects: 571
Study 30252913 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin DR (normalized efficacy)
Number of subjects: 571
Study 30252913 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin DR
Number of subjects: 571
Study 26468213 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (home treatment by video conferences)
Number of subjects: 40
Study 26468213 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient treatment
Number of subjects: 40
Study 24478238 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype group
Number of subjects: 37
Study 22652012 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 104
Study 22652012 — intervention group
Group type: COMPARATOR
Intervention: No reminders
Number of subjects: 104
Study 20400409 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir (1250/100 mg) + Ritonavir
Number of subjects: 208
Study 20400409 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir (750/100 mg) + Ritonavir
Number of subjects: 208
Study 20400409 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir (250/200 mg) + Ritonavir
Number of subjects: 208
Study 20400409 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir + Ritonavir
Number of subjects: 208
Study 18507270 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-White women
Number of subjects: 378
Study 18507270 — intervention group
Group type: COMPARATOR
Intervention: Control group (White women)
Number of subjects: 378
Study 18507270 — intervention group
Group type: COMPARATOR
Intervention: Angiographic disease progression
Number of subjects: 378
Study 18507270 — intervention group
Group type: COMPARATOR
Intervention: Survival without myocardial infarction
Number of subjects: 378
Study 15852175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound examination for PCL insufficiency (mfix)
Number of subjects: 40
Study 15852175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound examination for PCL insufficiency (ofix)
Number of subjects: 40
Study 15852175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound examination for ACL insufficiency
Number of subjects: 40
Study 15852175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound examination for ACL insufficiency (spontaneous ventral tibia translation)
Number of subjects: 40
Study 15852175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound examination for ACL insufficiency (normal resting value)
Number of subjects: 40
Study 12458862 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis Z9000 intraocular lens (Pharmacia)
Number of subjects: 2
Study 12458862 — intervention group
Group type: COMPARATOR
Intervention: AMO AR40e Opti‐Edge intraocular lens (AMO)
Number of subjects: 2
Study 10488481 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms iodide/day
Number of subjects: 752
Study 10488481 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.53 milligrams iodide/week
Number of subjects: 752
Study 10488481 — intervention group
Group type: EXPERIMENTAL
Intervention: up to 200 micrograms iodide/day
Number of subjects: 752
Study 10488481 — intervention group
Group type: EXPERIMENTAL
Intervention: suppressive hormone administration
Number of subjects: 752
Study 10488481 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of non-suppressive hormone therapy with low dose iodide (50-150 micrograms/day)
Number of subjects: 752
Study 10488481 — intervention group
Group type: EXPERIMENTAL
Intervention: mere iodide in doses of 200 micrograms/day
Number of subjects: 752
Study 10488481 — intervention group
Group type: COMPARATOR
Intervention: no therapy
Number of subjects: 752
Study 8703875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C (0.2 mg/ml solution for 3 minutes)
Number of subjects: 45
Study 8703875 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgical excision only)
Number of subjects: 45
Study 8703875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C
Number of subjects: 45
Study 8703875 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 1499364 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine (10-40 mg/d), enalapril (5-20 mg/d), and hydrochlorothiazide (12.5-25 mg/d) as necessary.
Number of subjects: 0
Study 1499364 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebos to active treatment).
Number of subjects: 0
Study 6089633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 195
Study 6089633 — intervention group
Group type: COMPARATOR
Intervention: Nafcillin plus tobramycin
Number of subjects: 195
Study 31280991 — intervention group
Group type: EXPERIMENTAL
Intervention: Blindfold training (routine practice + blindfold training)
Number of subjects: 0
Study 31280991 — intervention group
Group type: COMPARATOR
Intervention: Routine practice (control group)
Number of subjects: 0
Study 30304714 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive, high-dose IV iron (iron sucrose 400 mg/month unless ferritin > 700 μg/L and/or TSAT ≥40%)
Number of subjects: 2141
Study 30304714 — intervention group
Group type: COMPARATOR
Intervention: Reactive, low-dose IV iron (iron sucrose administered if ferritin <200 μg/L or TSAT < 20%)
Number of subjects: 2141
Study 30304714 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive, high-dose IV iron
Number of subjects: 2141
Study 30304714 — intervention group
Group type: COMPARATOR
Intervention: Reactive, low-dose IV iron
Number of subjects: 2141
Study 26962013 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 68
Study 26962013 — intervention group
Group type: COMPARATOR
Intervention: Control (standard best practice clinical care)
Number of subjects: 68
Study 24090048 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacha inchi oil (10 or 15 ml)
Number of subjects: 18
Study 24090048 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (10 or 15 ml)
Number of subjects: 18
Study 24090048 — intervention group
Group type: COMPARATOR
Intervention: Both oils
Number of subjects: 18
Study 22751085 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/benserazide, 100/25 mg with domperidone, 10 mg
Number of subjects: 18
Study 22751085 — intervention group
Group type: COMPARATOR
Intervention: levodopa/benserazide, 100/25 mg
Number of subjects: 18
Study 20920365 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Number of subjects: 169
Study 20920365 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Number of subjects: 169
Study 20920365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 20920365 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 169
Study 17566120 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosmotic macrogol electrolyte solution (MC-ES)
Number of subjects: 57
Study 17566120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 15598680 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (0.67 mg/d)
Number of subjects: 40
Study 12047731 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (600-800 mg on day 1 tapering to 200 mg)
Number of subjects: 136
Study 12047731 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (6-8 mg on day 1 tapering to 2 mg)
Number of subjects: 136
Study 12047731 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (for patients with multiple past detoxifications)
Number of subjects: 136
Study 12047731 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (for patients with multiple past detoxifications)
Number of subjects: 136
Study 12047731 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 136
Study 12047731 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 136
Study 9472648 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy
Number of subjects: 341
Study 7639218 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) 120 mg
Number of subjects: 190
Study 7639218 — intervention group
Group type: EXPERIMENTAL
Intervention: CBS plus amoxicillin (500 mg)
Number of subjects: 190
Study 7639218 — intervention group
Group type: EXPERIMENTAL
Intervention: CBS plus metronidazole (400 mg)
Number of subjects: 190
Study 7639218 — intervention group
Group type: EXPERIMENTAL
Intervention: CBS plus metronidazole and amoxicillin
Number of subjects: 190
Study 7639218 — intervention group
Group type: EXPERIMENTAL
Intervention: CBS plus metronidazole and tetracycline (500 mg)
Number of subjects: 190
Study 7639218 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-negative patients
Number of subjects: 190
Study 7639218 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with recrudescent infection
Number of subjects: 190
Study 2172401 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha preparations (combined)
Number of subjects: 178
Study 2172401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 790554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (150 mg daily for 14 days)
Number of subjects: 30
Study 790554 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (150 mg daily for 14 days)
Number of subjects: 30
Study 30902750 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 3.0 mg plus phentermine 15.0 mg
Number of subjects: 45
Study 30902750 — intervention group
Group type: COMPARATOR
Intervention: liraglutide plus placebo
Number of subjects: 45
Study 29211953 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth handle toothbrush
Number of subjects: 26
Study 29211953 — intervention group
Group type: COMPARATOR
Intervention: Grooved handle toothbrush
Number of subjects: 26
Study 25438930 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet
Number of subjects: 0
Study 22443479 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic-valve replacement (TAVR)
Number of subjects: 699
Study 22443479 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic-valve replacement
Number of subjects: 699
Study 20537748 — intervention group
Group type: EXPERIMENTAL
Intervention: VAL 320 mg/d
Number of subjects: 109
Study 20537748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 18264535 — intervention group
Group type: COMPARATOR
Intervention: Resin modified glass ionomer cement (RMGIC) with conventional Class I cavities
Number of subjects: 42
Study 18264535 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer cement (RMGIC) with modified cavities (1 mm straight bevel)
Number of subjects: 42
Study 15853436 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (160 microg/4.5 microg) in a single inhaler
Number of subjects: 1022
Study 15853436 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (200 microg)
Number of subjects: 1022
Study 15853436 — intervention group
Group type: COMPARATOR
Intervention: Formoterol (4.5 microg)
Number of subjects: 1022
Study 15853436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1022
Study 15853436 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 1022
Study 12608965 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene (PTFE)
Number of subjects: 129
Study 12608965 — intervention group
Group type: COMPARATOR
Intervention: Fluoropolymer coated Dacron
Number of subjects: 129
Study 12608965 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE in patients with critical limb ischaemia
Number of subjects: 129
Study 12608965 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE in patients with below-knee anastomosis
Number of subjects: 129
Study 12608965 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE with smaller (6 mm) diameter grafts
Number of subjects: 129
Study 12608965 — intervention group
Group type: COMPARATOR
Intervention: Fluoropolymer coated grafts
Number of subjects: 129
Study 12608965 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE
Number of subjects: 129
Study 10475617 — intervention group
Group type: EXPERIMENTAL
Intervention: HIDAC (High Dose Cytarabine)
Number of subjects: 162
Study 10475617 — intervention group
Group type: EXPERIMENTAL
Intervention: HIDAC + M (High Dose Cytarabine plus Mitoxantrone)
Number of subjects: 162
Study 8568427 — intervention group
Group type: EXPERIMENTAL
Intervention: Activator adjustment
Number of subjects: 30
Study 8568427 — intervention group
Group type: COMPARATOR
Intervention: Meric adjustment
Number of subjects: 30
Study 1775609 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine 200 mg or 400 mg
Number of subjects: 30
Study 1775609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7011362 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya-bean flour with 22 g saponins/kg
Number of subjects: 10
Study 7011362 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya-bean flour with 4 g saponins/kg
Number of subjects: 10
Study 29143157 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure Intervention (DI)
Number of subjects: 315
Study 29143157 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Case Management (ACCM)
Number of subjects: 315
Study 27423902 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of sweet beverages by the community pharmacy (intervention started on September 11, 2014)
Number of subjects: 123
Study 27423902 — intervention group
Group type: COMPARATOR
Intervention: Other food stores in the town (control)
Number of subjects: 123
Study 25516625 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin
Number of subjects: 39
Study 25516625 — intervention group
Group type: COMPARATOR
Intervention: 10 mg simvastatin plus 10 mg ezetimibe
Number of subjects: 39
Study 22814383 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine Structure Processing (FSP)
Number of subjects: 46
Study 22814383 — intervention group
Group type: COMPARATOR
Intervention: CIS+
Number of subjects: 46
Study 22814383 — intervention group
Group type: COMPARATOR
Intervention: HDCIS
Number of subjects: 46
Study 20829521 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 8
Study 20829521 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study 18055183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent infusion (600mg/12h)
Number of subjects: 16
Study 18055183 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (300mg intravenous loading dose + 900mg continuous infusion on Day 1, followed by 1200mg/daily from Day 2)
Number of subjects: 16
Study 15649191 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivudin (125 mg, once a day for 7 days)
Number of subjects: 2027
Study 15649191 — intervention group
Group type: COMPARATOR
Intervention: Famciclovir (250 mg, three times a day for 7 days)
Number of subjects: 2027
Study 15649191 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivudin
Number of subjects: 2027
Study 15649191 — intervention group
Group type: COMPARATOR
Intervention: Famciclovir
Number of subjects: 2027
Study 15649191 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivudin and Famciclovir
Number of subjects: 2027
Study 12867222 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg, increased to losartan 50 mg/HCTZ 12.5 mg at week 6 and losartan 100 mg/HCTZ 25 mg at week 12
Number of subjects: 857
Study 12867222 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg, increased to amlodipine 10 mg at week 6 and amlodipine 10 mg/HCTZ 25 mg at week 12
Number of subjects: 857
Study 12867222 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 857
Study 12867222 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 857
Study 10553839 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart patient-controlled analgesia system
Number of subjects: 0
Study 10553839 — intervention group
Group type: COMPARATOR
Intervention: Conventional patient-controlled analgesia system
Number of subjects: 0
Study 8705639 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovalbumin-stimulated peripheral blood mononuclear cells from egg-sensitive patients
Number of subjects: 2
Study 8705639 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2-stimulated peripheral blood mononuclear cells from egg-sensitive patients
Number of subjects: 2
Study 8705639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ovalbumin-stimulated and IL-2-stimulated peripheral blood mononuclear cells from egg-sensitive patients
Number of subjects: 2
Study 8705639 — intervention group
Group type: COMPARATOR
Intervention: Nonatopic healthy children
Number of subjects: 2
Study 1927197 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing before biopsy
Number of subjects: 300
Study 1927197 — intervention group
Group type: COMPARATOR
Intervention: Brushing after biopsy
Number of subjects: 300
Study 1927197 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy after brushing
Number of subjects: 300
Study 1927197 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined brushing and biopsy
Number of subjects: 300
Study 6612231 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic treatment with ampicillin 2 g X 4 + cloxacillin 1 g X 4 for 4 days
Number of subjects: 50
Study 6612231 — intervention group
Group type: COMPARATOR
Intervention: Control group without antibiotics
Number of subjects: 50
Study 31771589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (LWTC programme)
Number of subjects: 314
Study 31771589 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 314
Study 30157835 — intervention group
Group type: EXPERIMENTAL
Intervention: Long axis measurement
Number of subjects: 60
Study 26968844 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly
Number of subjects: 287
Study 26968844 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine 3 g daily
Number of subjects: 287
Study 25876342 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm acupuncture combined with auricular point sticking therapy
Number of subjects: 130
Study 25876342 — intervention group
Group type: COMPARATOR
Intervention: Estazolam tablets (0.5 to 1 mg)
Number of subjects: 130
Study 22595139 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous supplementation of a trace mineral supplement containing Zn, Mn, Se, and Cu at 230 days of gestation and 260 days of gestation
Number of subjects: 0
Study 22595139 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 20662910 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluoride toothpaste (500 p.p.m. F)
Number of subjects: 14
Study 20662910 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothpaste (1,000-1,500 p.p.m. F)
Number of subjects: 14
Study 17693150 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric training (CON)
Number of subjects: 54
Study 17693150 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training (ECC)
Number of subjects: 54
Study 17693150 — intervention group
Group type: COMPARATOR
Intervention: Untrained limb
Number of subjects: 54
Study 15536539 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 60
Study 15536539 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 60
Study 15536539 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 11900939 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen/elastin dermal substitute in combination with an autograft
Number of subjects: 29
Study 11900939 — intervention group
Group type: COMPARATOR
Intervention: Split-thickness autograft (control)
Number of subjects: 29